May 3rd 2024
Data also highlight a favorable overall survival trend with the acalabrutinib regimen in the phase 3 ECHO trial.
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Patient, Provider, and Caregiver Connection™: Individualizing Care for Patients with Schizophrenia—Understanding Patient Challenges and the Role of Innovative Treatment
View More
Improving Outcomes in Autoimmune Hemolytic Anemias at the Intersection Between Hematology and Oncology Care
View More
B-Cell Tumor Board: Rendering Real World Personalized Treatment Plans in CLL/SLL and MCL Through the Lens of Emerging BTKi Evidence
View More
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
Translating New Evidence into Treatment Algorithms from Frontline to R/R Multiple Myeloma: How the Experts Think & Treat
View More
Medical Crossfire®: The Experts Bridge Recent Data in Chronic Lymphocytic Leukemia With Real-World Sequencing Questions
View More
Community Practice Connections™: Pre-Conference Workshop on Immune Cell-Based Therapy
View More
Phase 3 CHRONOS-3 Study Meets Primary End Point for Indolent Non-Hodgkin’s Lymphoma
October 14th 2020The study is evaluating copanlisib (Aliqopa) in combination with rituximab (Rituxan) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after 1 or more prior lines of rituximab-containing therapy.
Study Identifies Characteristics of CAR T-Cell Products Associated with Outcomes in LBCL
October 7th 2020Researchers identified molecular and cellular characteristics of anti-CD19 CAR T-cell infusion products associated with how patients with large B-cell lymphoma respond to treatment and experience adverse events.
AUTO3, Pembrolizumab Combo Appears Safe, Elicits Durable Responses in Relapsed/Refractory DLBCL
September 27th 2020Results from the phase 1/2 ALEXANDER study found the investigational CAR T-cell product AUTO3 in combination with pembrolizumab to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.
sBLA Submitted for Loncastuximab Tesirine for Treatment of Relapsed/Refractory DLBCL
September 23rd 2020The submission is based on results from the phase 2 LOTIS 2 clinical trial, which is evaluating the efficacy and safety of loncastuximab tesirine in patients with relapsed or refractory DLBCL following at least 2 lines of prior systemic therapy.
NCCN Adds Tafasitamab-cxix in Combination with Lenalidomide to B-Cell Lymphoma Guidelines
August 26th 2020The updated guidelines now include tafasitamab-cxix in combination with lenalidomide with a category 2A designation as an option for the treatment of previously-treated adult patients with relapsed or refractory DLBCL not otherwise specified.
ASCO Expert on the Possible Benchmark Analysis of Autologous Transplantation in B-Cell Lymphomas
August 9th 2020Nirav Niranjan Shah, MD, discussed the analysis of autologous transplantation use in patients with relapsed, chemosensitive DLBCL and how it may become a comparator for other clinical trials.
Caron A. Jacobson, MD, on What Patients Should Know About the Phase 2 ZUMA-5 Study
July 14th 2020The expert in hematology discussed what patients should know about the study, which evaluated the use of axicabtagene ciloleucel (axi-cel) in patients with relapsed or refractory indolent non-Hodgkin lymphoma.
Allele-Specific DNA Methylation Mapping Reveals Possible Regulatory Sequence Polymorphisms
July 9th 2020Researchers found that dense allele-specific DNA methylation (ASM) mapping in normal samples plus cancer samples reveals possible candidate regulatory sequence polymorphisms (rSNPS) that are difficult to find by other approaches.
FDA Grants Priority Review to Pembrolizumab Monotherapy for Classical Hodgkin Lymphoma
July 9th 2020The FDA accepted and granted priority review to a supplemental biologics license application for pembrolizumab as monotherapy for the treatment of adult patients with relapsed or refractory classical Hodgkin lymphoma.
FDA Lifts Partial Clinical Hold on Pivotal Phase 2 Trial of Camidanlumab Tesirine
July 6th 2020The FDA lifted the partial clinical hold on the on the pivotal phase 2 trial of camidanlumab tesirine (Cami) – designed to evaluate the antibody drug conjugate in patients with relapsed or refractory Hodgkin lymphoma.
FDA Approves Tazemetostat for 2 Follicular Lymphoma Indications
June 18th 2020The FDA approved tazemetostat for adult patients with relapsed or refractory FL whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least 2 prior systemic therapies, as well as for adult patients with relapsed or refractory FL who have no satisfactory alternative treatment options.